Abstract
Gold nanoparticles (GNPs) exhibit promising potential for both cancer treatment and diagnosis. While the conjugation with tumor-targeting peptides enhances GNP functionality, there remains a need for further exploration of GNP transport and accumulation within tumors in vivo. This study focuses on the synthesis, characterization, cell binding, and biodistribution of GNPs adorned with a peptide targeting vascular endothelial growth factor receptor (VEGFR)-1/-2, named VGB3. The synthesized naked and VGB3-conjugated GNPs underwent through characterization using UV–Vis, DLS, FTIR, and TEM. Cellular analysis through immunocytochemistry and flow cytometry revealed that VGB3 and GNP-VGB3 selectively bound to VEGFR-1/-2-expressing human umbilical vein endothelial cells (HUVECs) and murine 4T1 mammary carcinoma tumor cells, with no affinity observed for VEGFR-1/-2-deficient HL-60 acute myeloid leukemia cell line. SPECT imaging of whole animals demonstrated specific accumulation of fluorescein isothiocyanate (FITC)-VGB3-decorated GNPs in 4T1 tumors. These results affirm the suitability of cell-specific peptides for targeted GNP delivery, emphasizing their potential in biomedical applications and targeted therapeutics.
Graphic abstract
Similar content being viewed by others
References
J. Folkman, Nat. Med. 1, 27–31 (1995)
T.W. Miller, J.S. Isenberg, D.D. Roberts, Chem. Rev. 109, 3099–3124 (2009)
L. Ai, C. Zhang, L. Li, J. Jiang, Appl. Catal. B-Environ. 148, 191–200 (2014)
Q. Sun, T. Ojha, F. Kiessling, T. Lammers, Y. Shi, Biomacromol 18, 1449–1459 (2017)
N. Ferrara, A.P. Adamis, Nat. Rev. Drug Discov. 15, 385–403 (2016)
Q. Feng, C. Zhang, D. Lum, J.E. Druso, B. Blank, K.F. Wilson, A. Welm, M.A. Antonyak, R.A. Cerione, Nat. Commun. 8, 14450 (2017)
G. Agarwal, R. Gabrani, Int. J. Pept. Res. Ther. 27, 149–168 (2021)
G. Zerbini, M. Lorenzi, A. Palini, New Engl. J. Med. 359, 763–764 (2008)
M. Gyurkovics, Z. Lohinai, A. Gyorfi, D.A. Székely, E. Dinya, A. Fazekas, L. Rosivall, Fogorv. Sz. 106, 53–59 (2013)
M. Shibuya, Endocr Metab Immune Disord Drug Targets 15, 135–144 (2015)
B.L. Ziegler, M. Valtieri, G.A. Porada, R. De Maria, R. Müller, B. Masella, M. Gabbianelli, I. Casella, E. Pelosi, T. Bock, E.D. Zanjani, C. Peschle, Science 285, 1553–1558 (1999)
B. Barleon, S. Sozzani, D. Zhou, H.A. Weich, A. Mantovani, D. Marmé, Blood 87, 3336–3343 (1996)
W.T. Bellamy, L. Richter, D. Sirjani, C. Roxas, B. Glinsmann-Gibson, Y. Frutiger, T.M. Grogan, A.F. List, Blood 97, 1427–1434 (2001)
P. Zanjanchi, S.M. Asghari, H. Mohabatkar, M. Shourian, M. Shafiee Ardestani, J. Nanobiotechnol. 20, 7 (2022)
A. Sadremomtaz, A.M. Ali, F. Jouyandeh, S. Balalaie, R. Navari, S. Broussy, K. Mansouri, M.R. Groves, S.M. Asghari, Signal Transduct. Target. Ther. 5, 76 (2020)
A.D. AlQahtani, D. O’Connor, A. Domling, S.K. Goda, Biomed. Pharmacother. 113, 108750 (2019)
A. Babaei, S.M. Mousavi, M. Ghasemi, N. Pirbonyeh, M. Soleimani, A. Moattari, Life Sci. 284, 119652 (2021)
R.R. Arvizo, S. Saha, E. Wang, J.D. Robertson, R. Bhattacharya, P. Mukherjee, Proc. Natl. Acad. Sci. U.S.A. 110, 6700–6705 (2013)
H. Daraee, A. Eatemadi, E. Abbasi, S. Fekri Aval, M. Kouhi, A. Akbarzadeh, Artif. Cells Nanomed. Biotechnol. 44, 410–422 (2016)
M. Shourian, H. Ghourchian, M. Boutorabi, J. Anal. Chim. Acta. 895, 1–11 (2015)
S. Ashraf, B. Pelaz, P. del Pino, M. Carril, A. Escudero, W.J. Parak, M.G. Soliman, Q. Zhang, C. Carrillo-Carrion, Top. Curr. Chem. 370, 169–202 (2016)
R.S. Darweesh, N.M. Ayoub, S. Nazzal, Int. J. Nanomed. 14, 7643–7663 (2019)
M. Shourian, H. Ghourchian, M. Boutorabi, Anal. Chim. Acta 895, 1–11 (2015)
J. Turkevich, P.C. Stevenson, J. Hillier, Faraday Discuss. 11, 55–75 (1951)
S. Balakrishnan, F. Bhat, P. Raja Singh, S. Mukherjee, P. Elumalai, S. Das, C. Patra, J. Arunakaran, Cell Prolif. 49, 678–697 (2016)
M. Farzaneh Behelgardi, S. Zahri, F. Mashayekhi, K. Mansouri, S.M. Asghari, Sci. Rep. 8, 17924 (2018)
Y. Zheng, S. Ji, A. Czerwinski, F. Valenzuela, M. Pennington, S. Liu, Bioconjug. Chem. 25, 1925–1941 (2014)
S.M. Ansar, S. Chakraborty, C.L. Kitchens, Nanomaterials 8(5), 339 (2018)
S. Kalmodia, S. Vandhana, B.R. Tejaswini Rama, B. Jayashree, T. Sreenivasan Seethalakshmi, V. Umashankar, W. Yang, C.J. Barrow, S. Krishnakumar, S.V. Elchuri, Cancer Nanotechnol. 7, 1 (2016)
B. Yahyaei, P. Pourali, Sci. Rep. 9, 10242 (2019)
A.G. Rad, H. Abbasi, M.H. Afzali, Phys. Procedia 22, 203–208 (2011)
S.B. Rice, C. Chan, S.C. Brow, P. Eschbach, L. Han, D.S. Ensor, A.B. Stefaniak, J. Bonevich, A.E. Vladár, A.R. Hight Walker, J. Zheng, C. Starnes, A. Stromberg, J. Ye, E.A. Grulke, Metrologia 50, 663–678 (2013)
E. Assareh, F. Mehrnejad, K. Mansouri, A.R. Esmaeili Rastaghi, H. Naderi-Manesh, S.M. Asghari, Biochem. J. 476, 645–663 (2019)
W. Haiss, N.T. Thanh, J. Aveyard, D.G. Fernig, Anal. Chem. 79, 4215–4221 (2007)
M. Simons, E. Gordon, L. Claesson-Welsh, Nat. Rev. Mol. Cell Biol. 17, 611–625 (2016)
Z. Bacsik, J. Mink, G. Keresztury, Appl. Spectros. Rev. 39, 295–363 (2004)
J. Jin, M. Ovais, C. Chen, NanoToday 22, 83–99 (2018)
R. Masood, J. Cai, T. Zheng, D.L. Smith, D.R. Hinton, P.S. Gill, Blood 98, 1904–1913 (2001)
Acknowledgements
The authors are grateful to the University of Tehran and Payame Noor University for their support. The authors would like to acknowledge the Preclinical Lab, Core Facility, Tehran University of Medical Sciences, Tehran, Iran, for providing this research's in vivo imaging and image processing services.
Author information
Authors and Affiliations
Contributions
SMA, MF, PZ contributed to conceptualization. SMA, MSA, PZ contributed to methodology. RN-M-F and PZ contributed to software. SMA, MSA, PZ contributed to validation. PZ contributed to formal analysis. RN-M-F contributed to investigation; SMA, MSA contributed to resources. RN-M-F and PZ contributed to data curation. SMA contributed to writing-original draft; SMA, PZ contributed to writing-review and editing. MSA contributed to visualization; SMA contributed to supervision; and SMA, MF contributed to project administration.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare the patent application (US Patent and Trademark Office, Patent No 10745454 [Method of synthesizing antagonist peptides for cell growth]).
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Navidi-Moghadam-Foumani, R., Fazilati, M., Shafiee Ardestani, M. et al. Gold nanoparticle conjugation and tumor accumulation of a VEGF receptor-targeting peptidomimetic. J IRAN CHEM SOC 21, 293–303 (2024). https://doi.org/10.1007/s13738-023-02925-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13738-023-02925-4